https://www.selleckchem.com/products/vy-3-135.html
viticola secretes PvRXLR53 to suppress host immunity from the very early stage of infection. To assess the cost-effectiveness of corneal collagen cross-linking (CXL) versus no CXL for keratoconus in the United States (US). A discrete-event microsimulation was developed to assess the cost-effectiveness of corneal cross-linking (CXL, Photrexa + KXL combination product) versus no CXL for patients with keratoconus. The lifetime model was conducted from a US payor perspective. The source for CXL efficacy and safety data was a 12-month rando
Like
Comment
Share
